Leqembi

E25439
Alzheimer’s disease drug drug monoclonal antibody

Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (5)

Label Occurrences
lecanemab 8
Leqembi canonical 7
Lecanemab 2

Statements (48)

Predicate Object
instanceOf Alzheimer’s disease drug ⓘ
drug ⓘ
monoclonal antibody ⓘ
administeredTo adult patients ⓘ
approvedBy Food and Drug Administration ⓘ
surface form: U.S. Food and Drug Administration
belongsToTherapeuticArea neurodegenerative diseases ⓘ
neurology ⓘ
coDevelopedBy Eisai and Biogen ⓘ
developedBy Biogen ⓘ
Eisai ⓘ
hasATCClass N06DX ⓘ
hasBiomarkerTarget amyloid-beta protofibrils ⓘ
hasBrandOwner Eisai ⓘ
hasCommonAdverseEffect ARIA-E (amyloid-related imaging abnormalities with edema) ⓘ
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits) ⓘ
headache ⓘ
infusion-related reactions ⓘ
hasContraindicationNote caution in patients on anticoagulant therapy ⓘ
hasCoPromotionPartner Biogen ⓘ
hasCountryOfApproval United States of America ⓘ
surface form: United States
hasDosageForm solution for intravenous infusion ⓘ
hasDosingFrequency every two weeks ⓘ
hasDrugClass anti-amyloid beta monoclonal antibody ⓘ
hasEffect slows cognitive decline compared with placebo in early Alzheimer’s disease ⓘ
hasFDAIndicationText treatment of Alzheimer’s disease ⓘ
hasGenericName Leqembi self-linksurface differs ⓘ
surface form: lecanemab
hasIndication Alzheimer's disease ⓘ
surface form: Alzheimer’s disease

mild cognitive impairment due to Alzheimer’s disease ⓘ
mild dementia stage of Alzheimer’s disease ⓘ
hasINN Leqembi self-linksurface differs ⓘ
surface form: lecanemab
hasKeyClinicalTrial CLARITY AD ⓘ
Study 201 ⓘ
Study 301 ⓘ
hasMolecularType humanized IgG1 monoclonal antibody ⓘ
hasRegulatoryPathway FDA traditional approval ⓘ
hasRegulatoryStatus FDA approved ⓘ
hasRouteOfAdministration intravenous infusion ⓘ
hasWarning risk of ARIA ⓘ
indicatedFor early-stage Alzheimer’s disease ⓘ
isAdministeredIn hospital or infusion center settings ⓘ
isFirstInClass first anti-amyloid Alzheimer’s drug with full FDA approval (as of 2023) ⓘ
isUsedWith MRI monitoring for ARIA ⓘ
mechanismOfAction binds aggregated soluble and insoluble amyloid-beta ⓘ
reduces amyloid-beta plaques in the brain ⓘ
previouslyHadRegulatoryPathway FDA accelerated approval ⓘ
requires confirmation of amyloid-beta pathology ⓘ
targets amyloid-beta ⓘ
amyloid-beta plaques ⓘ

Referenced by (19)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen → hasProduct → Leqembi ⓘ
Leqembi → hasGenericName → Leqembi self-linksurface differs ⓘ
this entity surface form: lecanemab
Leqembi → hasINN → Leqembi self-linksurface differs ⓘ
this entity surface form: lecanemab
Eisai → hasProduct → Leqembi ⓘ
this entity surface form: Lecanemab
Eisai → hasProduct → Leqembi ⓘ
Eisai → developed → Leqembi ⓘ
this entity surface form: Lecanemab
Eisai → developed → Leqembi ⓘ
Eisai → developedForIndication → Leqembi ⓘ
this entity surface form: Leqembi – Alzheimer’s disease
CLARITY AD → evaluatesDrug → Leqembi ⓘ
this entity surface form: lecanemab
CLARITY AD → evaluatesDrug → Leqembi ⓘ
CLARITY AD → drugBrandName → Leqembi ⓘ
CLARITY AD → drugGenericName → Leqembi ⓘ
this entity surface form: lecanemab
Study 301 → evaluatesDrug → Leqembi ⓘ
Study 301 → evaluatesDrug → Leqembi ⓘ
this entity surface form: lecanemab
Study 301 → sponsorDrugBrand → Leqembi ⓘ
Study 301 → sponsorDrugGeneric → Leqembi ⓘ
this entity surface form: lecanemab
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits) → associatedWith → Leqembi ⓘ
subject surface form: ARIA-H
this entity surface form: lecanemab
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits) → associatedWith → Leqembi ⓘ
subject surface form: ARIA-H
this entity surface form: donanemab
Eisai and Biogen → developed → Leqembi ⓘ
this entity surface form: lecanemab